Search research articles
Contact Us
Filters
Showing results (31-40 of 226) with videos related to
Page
of 23
Sort By:
Arthritis and Rheumatism
|
February 7, 2003
Macrophage migration inhibitory factor: an emerging therapeutic target in rheumatoid arthritis
Eric F Morand, Richard Bucala, Michelle Leech
Nature Reviews. Drug Discovery
|
April 22, 2006
MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis
Eric F Morand, Michelle Leech, Jürgen Bernhagen
Lupus Science & Medicine
|
September 1, 2015
Characteristics of azathioprine use and cessation in a longitudinal lupus cohort
Lucy Croyle, Alberta Hoi, Eric F Morand
The Medical Journal of Australia
|
March 17, 2017
The Australian Lupus Registry and Biobank: a timely initiative
Sean O'Neill, Eric F Morand, Alberta Hoi
Rheumatic Diseases Clinics of North America
|
July 3, 2021
Systemic Lupus Erythematosus Outcome Measures for Systemic Lupus Erythematosus Clinical Trials
Taraneh Tofighi, Eric F Morand, Zahi Touma
Frontiers in Immunology
|
August 6, 2019
Could GILZ Be the Answer to Glucocorticoid Toxicity in Lupus?
Jacqueline K Flynn, Wendy Dankers, Eric F Morand
Nature Clinical Practice. Rheumatology
|
February 1, 2008
Mechanisms of disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis
Sally Ayoub, Michael J Hickey, Eric F Morand
The Journal of Rheumatology
|
January 17, 2017
Quality of Care for Systemic Lupus Erythematosus: Mind the Knowledge Gap
Vera Golder, Eric F Morand, Alberta Y Hoi
Expert Opinion on Biological Therapy
|
July 22, 2025
Progress in the use of type I interferon blockade in systemic lupus erythematosus
Iolanda Miceli, Eric F Morand, Sarah A Jones
Immunology and Cell Biology
|
January 11, 2012
BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus
Fabien B Vincent, Eric F Morand, Fabienne Mackay
Page
of 23
Search research articles
Search
Showing results (31-40 of 226) with videos related to
Sort By:
Page
of 23
Arthritis and Rheumatism
|
February 7, 2003
Macrophage migration inhibitory factor: an emerging therapeutic target in rheumatoid arthritis
Eric F Morand, Richard Bucala, Michelle Leech
Nature Reviews. Drug Discovery
|
April 22, 2006
MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis
Eric F Morand, Michelle Leech, Jürgen Bernhagen
Lupus Science & Medicine
|
September 1, 2015
Characteristics of azathioprine use and cessation in a longitudinal lupus cohort
Lucy Croyle, Alberta Hoi, Eric F Morand
The Medical Journal of Australia
|
March 17, 2017
The Australian Lupus Registry and Biobank: a timely initiative
Sean O'Neill, Eric F Morand, Alberta Hoi
Rheumatic Diseases Clinics of North America
|
July 3, 2021
Systemic Lupus Erythematosus Outcome Measures for Systemic Lupus Erythematosus Clinical Trials
Taraneh Tofighi, Eric F Morand, Zahi Touma
Frontiers in Immunology
|
August 6, 2019
Could GILZ Be the Answer to Glucocorticoid Toxicity in Lupus?
Jacqueline K Flynn, Wendy Dankers, Eric F Morand
Nature Clinical Practice. Rheumatology
|
February 1, 2008
Mechanisms of disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis
Sally Ayoub, Michael J Hickey, Eric F Morand
The Journal of Rheumatology
|
January 17, 2017
Quality of Care for Systemic Lupus Erythematosus: Mind the Knowledge Gap
Vera Golder, Eric F Morand, Alberta Y Hoi
Expert Opinion on Biological Therapy
|
July 22, 2025
Progress in the use of type I interferon blockade in systemic lupus erythematosus
Iolanda Miceli, Eric F Morand, Sarah A Jones
Immunology and Cell Biology
|
January 11, 2012
BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus
Fabien B Vincent, Eric F Morand, Fabienne Mackay
Page
of 23